Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 11, 2012, Pages

  Mead, Gillian E ^a   Hsieh, Cheng Fang ^b   Lee, Rebecca ^c   Kutlubaev, Mansur A ^c   Claxton, Anne ^d   Hankey, Graeme J ^d   Hackett, Maree L ^e  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d ROYAL PERTH HOSPITAL   (Australia)

^e GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ANXIETY; CEREBROVASCULAR ACCIDENT; COGNITION; DEPRESSION; DRUG EFFECT; HUMAN; META ANALYSIS; NEUROLOGIC DISEASE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADULT; ANXIETY; CITALOPRAM; COGNITION; DEPRESSION; FLUOXETINE; HUMANS; NERVOUS SYSTEM DISEASES; PAROXETINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STROKE;

EID: 84873137278     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009286.pub2     Document Type: Review

References (167)

1. Acler M, Avesani A, Fiaschi A, Manganotti P. Serotonergic modulation of brain excitability and motor recovery in patients affected by stroke. A double blind placebo RCT. International Journal of Stroke 2008;3:336.
2. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind placebo RCT to investigate the effects of serotonergic modulation on brain excitability and motor recovery in stroke patients. Journal of Neurology 2009;256:1152-8.
3. Almeida OP, Waterreus A, Hankey GJ. Preventing depression after stroke: results from a randomized placebo-controlled trial. Journal of Clinical Psychiatry 2006;67(7):1104-9.
4. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with selective serotonin reuptake inhibitors. Journal of Neurology 1994;241:S42.
5. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of post-stroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25(6):1099-104.
6. Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram. Acta Neurologica Scandinavica 1994;89 Suppl 155:20.
7. Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram - a selective serotonin reuptake inhibitor. Canadian Journal of Neurological Sciences 1993;20:S115.
8. Andersen G, Vestergaard K, Lauritzen L. Post-stroke depression treated with citalopram a selective serotonin reuptake inhibitor. Proceedings of the 7th Scandinavian Meeting on Cerebrovascular Disease. 1993:54.
9. Andersen G, Vestergaard K, Lauritzen LU. Effective treatment of depression following apoplexy with citalopram. Ugeskrift for Laeger 1995;157(14):2000-3.
10. Flicker C, Andersen G, Bayer L. A placebo controlled study of citalopram treatment for post-stroke depression. Proceedings of the 11th Annual Meeting of the American Association for Geriatric Psychiatry. 1998.
11. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica 1998;98(6):455-8.
12. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry 1999;14(8):681-5.
13. Chen WY, Liu FY, Yang AP. Study of effect of integrative Chinese herbs with fluoxetine on rehabilitation of neurological impairment in patients with post-stroke depression. Journal of Chengdu University of Traditional Chinese Medicine 2001;24(4):20-3.
14. Chen W, Wang G-F, Chen X-H, Sheng Y-L, Zhu H. Effects of paroxetine on function recovery in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation 2002;6(13):2014-5.
15. Cheng F, Shao G, Bao S. Study of effect on neurologic function rehabilitation in patient with post-stroke depression. Chinese Journal of Clinical Rehabilitation 2003;7(1):108-9.
16. Chen KN. Changes of neurotransmitter in patients with post-stroke depression observed with encephalofluctuography technology. Chinese Journal of Clinical Rehabilitation 2005;9(16):118-9.
17. Chen T, Li J, Han M. A study on paroxetine in the treatment for post-stroke depression. Jiangxi Medicine 2005;40(7):382-4.
18. Chollet F, Tardy J, Albucher J-F, Thalamas E, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurology 2011;10:123-30.
19. Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27(7):1211-4.
20. Feng B-L, Wang Q-C, Zheng-Yuan LI. Influence of Jieyu Huoxue decoction on rehabilitation of patients with depression after cerebral infarction. Journal of Chinese Integrated Medicine 2004;2(3):182-4.
21. Finkenzeller W, Zobel I, Rietz S, Schramm E, Berger M. Interpersonal psychotherapy and pharmacotherapy for post-stroke depression. Feasibility and effectiveness. Der Nervenarzt 2009;80(7):805-12.
22. Fruehwald S, Gatterbauer. Early fluoxetine treatment of post-stroke depression: a three-month double-blind placebo-controlled study with an open-label long-term follow up. Journal of Neurology 2003;250(3):347-51.
23. GlaxoSmithKline. An 8-week double-blind placebo controlled parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from depression following stroke. GSK Clinical Study Register www.gsk clinicalstudyregister.com (accessed 31 August 2012).
24. Guo R-Y, Su L, Wang CX. Effects of Linggui Bafa on the therapeutic effect and quality of life in patients of post-stroke depression. Chinese Acupuncture & Moxibustion 2009;29(10):785-90.
25. He P. Randomized controlled observation on the effect of early application of fluoxetine in preventing depression after stroke. Chinese Journal of Clinical Rehabilitation 2004;8(28):6016-7.
26. He Y, Wang X, Xiao C. Prospective study of effects of paroxetine with mental intervention on depression and anxiety after stroke. Nervous Diseases and Mental Health 2005;5(1):6-13.
27. Wang X, He Y, Xiao C-L. A clinical trial of paroxetine and psychotherapy in patients with post-stroke depression and anxiety. Chinese Mental Health journal 2005;19:564-6.
28. Hu Y, Suo A, Xiang L. The comparative study of the effectiveness of fluoxetine on the stroke patients with depressive symptoms. Shanghai Archives of Psychiatry 2002;14:149-50.
29. Huang X-H. The clinical correlation study and the effect of fluoxetine intervention on poststroke depression. Chinese Journal of Clinical Rehabilitation 2002;6(15):2296-7.
30. Ji QM, Xie LP. Efficacy of fluoxetine in the treatment of 20 patients with depression after stroke. Herald of Medicine 2000;19(4):329.
31. Jia W. Effect of early intervention on recovery of motor function and recurrent stroke in patients with post-stroke depression. Chinese Journal of Clinical Rehabilitation 2005;9(12):4-5.
32. Kong Y. Fluoxetine for poststroke depression: a randomized placebo controlled clinical trial. Neural Regeneration Research 2007;2(3):162-5.
33. Lai J. The effect of using paroxetine to treat post stroke depression. Journal of Guangdong Medical College 2006;24(6):585-6.
34. Li F, Gu DX, Ceng SH, Xu JW. Effect of paroxetine on prognosis of patients with post cerebral infarction depression. Chinese Journal of New Drugs and Clinical Remedies. 2002;21(1):11-3.
35. Li J, He Q-Y, Han M-F. Recent effect of fluoxetine in improving neurologic impairment and preventing post-stroke depression in the early stage. Chinese Journal of Clinical Rehabilitation 2004;8(7):1208-9.
36. Li C-M, Jiang X-D, Liao G, Lei J-M, Lan S, Ni F-W. Effect of antidepressant drugs in early period on the recovery of post-stroke depression. Chinese Journal of Clinical Rehabilitation 2004;8(19):3713-5.
37. Li Y, Wang X, Qian FS. Related factors of post-stroke depression and effect of paroxetine. Shandong Archives of Psychiatry 2005;18(4):209-10.
38. Li W-Q, Li D-X. The efficacy of citalopram for post-stroke depression and its effects on stroke rehabilitation. International Journal of Cerebrovascular Diseases 2006;14(4):275-8.
39. Li L-T, Wang S-H, Ge H-Y, Chen J, Yue S-W, Yu M. The beneficial effects of the herbal medicine free and easy wanderer plus (FEWP) and fluoxetine on post-stroke depression. Journal of Alternative and Complementary Medicine 2008;14(7):841-6.
40. Liang Z, Shuliang T. Clinical efficacy of fluoxetine in treatment of patients with depression after acute stroke. Chinese Journal of Clinical Rehabilitation 2003;7(13):1924-5.
41. Liu L-X. Recent effect of drug intervention on post-stroke anxiety. Chinese Journal of Clinical Rehabilitation 2004;8(30):6600-1.
42. Liu Y, Xu R. Effect of citalopram treatment on post-stroke depression and neurological functional rehabilitation. Chinese Journal of Rehabilitation 2006;21(3):174-5.
43. Meara RJ, Thalanany M, Balonwu V, Hobson P. The treatment of depression after stroke with the selective serotonin reuptake inhibitor sertraline. Cerebrovascular Diseases 1998;8 Suppl 4:90.
44. Miao S-Y, Shi Y-J. Related factors of post-stroke depression and therapeutical effect of citalopram. Chinese Journal of Clinical Rehabilitation 2004;8(19):3718-9.
45. Murray V, von Arbin M, Bartfai A, Berggren A-L, Landtblom A-M, Lumdmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry 2005;66:708-16.
46. Guiraud-Chaumeil B, Pariente J, Albucher J-F, Loubinoux I, Chollet F. Rehabilitation after stroke [Recuperation neurologique post-ischemique]. Bulletin de l'Académie Nationale de Médecine 2002;6:1015-24.
47. Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Annals of Neurology 2001;50(6):718-29.
48. Rasmussen A. Depression and stroke. Nordic Journal of Psychiatry 2001;55(4):288.
49. Rasmussen A. Prophylactic treatment for post-stroke depression and comorbidity. Journal of Psychosomatic Research 2000;48(3):66.
50. Rasmussen A, Lunde M, Poulsen D, Sorensen K, Qvitzau S, Bech P. A double-blind placebo controlled study of sertraline in the prevention of depression in stroke patients. European Neuropyschopharmacology 2002;12:231.
51. Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003;44:216-22.
52. Restifo DA, Lo Prest R, Lanza S, Giuffrida S, D'Aleo G, Rifici Di Bella C, et al. Motor cortex reorganization induced by fluoxetine in poststroke hemiplegic patients undergoing rehabilitation therapy: a study with transcranial magnetic stimulation. Neurorehabilitation and Neural Repair 2001;15(4):284.
53. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry 2003;160:1823-9.
54. Narushima K, Kosier JT, Robinson RG. Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases 2002;190:296-303.
55. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry 2000;157(3):351-9.
56. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and post-stroke depression: a placebo controlled trial of antidepressants. American Journal of Psychiatry 2003;160:1823-9.
57. Narushima K, Robinson RG. Preventing post-stroke depression: a 12 week double blind randomised treatment trial and 21 month follow-up. Journal of Nervous and Mental Diseases 2002;190:296-303.
58. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. American Journal of Psychiatry 2000;157(3):351-9.
59. Jorge RE, Acion L, Moser D, Adams HP, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Archives of General Psychiatry 2010;67(2):187-96.
60. Robinson RG, Arndt S. Incomplete financial disclosure in a study of escitalopram and problem solving therapy for prevention of post-stroke depression. JAMA 2009;301:1023-4.
61. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression. JAMA 2008;299(20):2391-400.
62. Song J-G. Effects of fluoxetine hydrochloride on depressive symptoms and P300 after cerebral stroke. Chinese Journal of Clinical Rehabilitation 2006;10(14):160-2.
63. Wang X, Tan Z, Wu Z, Gao J, Feng M. The effects of anti-depression therapy on post-stroke depression and neurologic rehabilitation in the elderly patients. Chinese Journal of Geriatrics 2003;22(5):270-3.
64. Wen Z-X. The influence of post-stroke prophylactic anti-depression treatment on nerve functional rehabilitation. Acta Academiae Medicinae Qingdao Universitatis 2006;42(3):253-4.
65. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M. Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31(8):1829-32.
66. Xie R, Liu J, Quan H. A prospective random clinical contrast study of treatment with sertraline in elderly patients with post-stroke depression. Chinese Journal of Clinical Neuroscience 2005;13(3):294-7.
67. Xu J, Tan J, Ou L. A study on treatment of fluoxetine to depression in early recovery stage of cerebral infarction. Chinese Journal of Rehabilitation Medicine 2001;16(5):281-3.
68. Xu J, Wang J, Liu J. Preventive effects of antidepressants on post-stroke depression. Chinese Mental Health Journal 2006;20(3):186-8.
69. Xu B, Zhou WY, Zhang SJ. Observation on effect of Wuling capsule in treating poststroke depression. Chinese Journal of Integrated Traditional and Western Medicine 2007;27(7):640-2.
70. Yang J, Zhao Y, Bai S. Controlled study on antidepressant treatment of patients with post-stroke depression. Chinese Mental Health Journal 2002;16(12):871-2.
71. Yang J. Therapeutic effect of paroxetine on patients with early poststroke depression and the serum interleukins. Chinese Journal of Cerebrovascular Diseases 2011;8(5):235-8.
72. Ye L-X, Wang H, Wang Y-D, Zhong L, Liang D-S, Guo Y. Effect of anti-depressive therapy on the rehabilitation of psychological and neurological function after stroke. Chinese Journal of Clinical Rehabilitation 2004;8(31):6826-8.
73. Ye LX. Effect of Paxil and berhomine on post-stroke anxiety-depression and neurological recovery. Chinese Journal of Clinical Rehabilitation 2006;10(6):153-5.
74. Zhou B. Effects of fluoxetine on neurofunctional recovery of nondepressed patients after stroke. Chinese Journal of Clinical Rehabilitation 2003;7(3):374-5.
75. Zhou Z-l, Liang L-Z, Yan Y-X. Preventive effects of fluoxetine on post-stroke depression. Chinese Journal of Modern Applied Pharmacy 2008;25(3):263-4.
76. Berends HI, Nijlant JMM, van Putten MJAM, Movig KLL, IJzerman MJ. Single dose of fluoxetine increases muscle activation in chronic stroke patients. Clinical Neuropharmacology 2009;32(1):1-5.
77. Ijzerman MJ, van Gendereren HI, Nijlant JJM. Effect of a single dose of the SSRI fluoxetine on motor activation patterns of the upper extremity in chronic stroke patients. Neurorehabilitation and Neural Repair 2006;20:158.
78. Bian X, Zhu GZ, Liu Y, Hu XQ. Meclofenoxate combined with fluoxetine vs fluoxetine alone in treatment of depression after cerebral infarction. Chinese Journal of New Drugs and Clinical Remedies. 2006;25(5):372-5.
79. Chen SD. Role of fluoxetine hypochloride and clomipramine in ameliorating vascular depression and the side effects. Chinese Journal of Clinical Rehabilitation 2005;9(20):24-5.
80. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases 2008;26(3):266-71.
81. Cui DD. Depression associated with cerebral stroke. Hong Kong Medical Journal 2001;7(4):32.
82. Ding D, Zhang Z, Liu H. Combination of paroxetine and psychotherapy in the treatment of post-stroke depression. Shanghai Archives of Psychiatry 2005;17(2):89.
83. Erfurth A. Treatment of depressive disorders in neurological rehabilitation: effects of paroxetine. Psychiatrische Praxis 2001;28(1):43-4.
84. Fedin AI, Krasnoperov EN, Podobedova NS. Coaxil efficacy in depression in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2004;10:67-8.
85. Influence of a single dose of fluoxetine on brain activity during movement observation and execution, muscle activity and motor function in chronic stroke patients. www.clinicaltrialregister.eu.
86. Gao X-J. Effects of fluoxetine on the depressive symptoms, self-care ability of daily life and neurological function in stroke patients. Chinese Journal of Clinical Rehabilitation 2005;9(16):12-3.
87. Gekht AB, Bogolepova AN, Sorokina IB. Post-stroke depression: an experience in using cipramil. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 2002;5:36-9.
88. Gonzalez-Torrecillas JL, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. International Psychogeriatrics 1995;7(4):547-60.
89. Havle N. Escitalopram in treatment of post-stroke depression. Klinik Psikofarmakoloji Bulteni 2010;20(1):74-8.
90. He X. Approaches to the treatment methods of post-stroke depression. Modern Rehabilitation 2001;5(8):34-5.
91. He W, Cai D, Lin L, Fang Y, Zheng X. Clinical studies on event-related potentials (ERPs) N400 and the related factors in patients with poststroke depression (PSD). International Journal of Psychiatry in Medicine 2010;40(3):349-59.
92. He Y, Zhao B, Wang S. Comparative study on paroxetine and amitriptyline in treatment of post-stroke depression. Chinese Journal of Integrative Medicine on Cardio Cerebrovascular Disease 2004;2(2):76-7.
93. Hong JF, Li Jl. Comparison of the curative effects of yuxingchangzhi tang and fluoxetine in the treatment of post-stroke depression. Chinese Journal of Clinical Rehabilitation 2004;8(13):2504-5.
94. Horváth S, Karányi Z, Harcos P, Nagy Z, Németh G, Andor G. Clinical evaluation of the efficacy and safety of paroxetine in poststroke depression: results from a phase 4, open label, multicentre clinical trial with 26 weeks of follow-up. Orvosi Hetilap 2006;147(50):2397-404.
95. Hu TT, Zhu SQ. Effect of fluoxetine on the depressive status and quality of life in patients with stroke. Chinese Journal of Clinical Rehabilitation 2004;9(12):6-7.
96. Kimura M, Kanetani K, Imai R, Suzuki H, Isayama K, Endo S. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. International Clinical Psychopharmacology 2002;17(3):121-5.
97. Liang S-Q, Peng X-S, Yang J-H. Influence of antidepressant treatment on the cognitive function and cerebral blood flow in patients with post-stroke depression. Zhongguo Linchuang Kangfu 2005;9(16):20-1.
98. Liu G, Liu R, Wang Y, He G. Clinical control study of citalopram and amitriptyline in the treatment of post-stroke depression. Journal of Clinical Psychological Medicine 2006;16(3):153-4.
99. Liu X, Ji Q, Wang J. A comparative study of citalopram and amitriptyline in post-stroke depression. Journal of Clinical Psychological Medicine 2004;14(2):8-81.
100. Li W, Chen Z, Shan B. Comparison of therapeutic effects of domestic and imported fluoxetine in treatment of post-stroke depression. Chinese New Drugs Journal 1999;8(3):193-5.
101. Loubinoux I. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. NeuroImage 2002;15(1):26-36.
102. Luo R, Hu C, Chen R. Effect of paroxetine on post-stroke depression. Chinese Journal of Rehabilitation 2006;12(7):597-8.
103. Marko MG. Antidepressant treatment for post-stroke depression. Neuropsychopharmacology 1994;10(3S Pt 2):177S.
104. Mei G, Lu R, Ye Q, Li HL. A controlled trial comparing the total rehabilitation of paroxetine and fluoxetine in the treatment of post stroke depression. Health Psychology Journal 2001;9(6):461-3.
105. Mitchell PH, Becker KJ, Buzaitis A, Cain KC, Fruin M, Kohen R, et al. Brief psychosocial/behavioral intervention with antidepressant reduces post-stroke depression significantly more than antidepressant alone. Stroke 2008;39:543.
106. Miyai I, Reding MJ. Effects of antidepressants on functional recovery following stroke: a double blind study. Journal of Neurologic Rehabilitation 1998;12:5-13.
107. Mo WY, Yu HY, Yang Y. Comparison of Saint John's Wort extract with fluoxetine in the treatment of post-stroke depression. Chinese Journal of New Drugs 2004;13(10):942-4.
108. Ooboshi H, Ota K, Kusuda K, Ishikawa E, Kumai Y, Kamouchi M. Treatment of post-stroke depression during rehabilitation: a preliminary randomized study with SSRI. International Journal of Stroke 2008;3(1):350-1.
109. Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology 2004;173(1-2):73-8.
110. Ruddell M. Fluoxetine vs placebo for depressive symptoms after stroke: failed randomised controlled trial. International Journal of Geriatric Psychiatry 2007;22(10):963-5.
111. Sato S, Yamakawa Y, Terashima Y, Ohta H, Asada T. Efficacy of milnacipran on cognitive dysfunction with post-stroke depression: preliminary open-label study. Psychiatry and Clinical Neurosciences 2006;60(5):584-89.
112. Shan P, Liu S, Chi Z. Effect of fluoxetine on treatment of post-stroke depression. Acta Academiae Medicinae Shandong 2001;39(3):229-30.
113. Simis S, Nitrini R. Cognitive improvement after treatment of depressive symptoms in the acute phase of stroke. Arquivos de Neuro-Psiquiatria 2006;64(2B):412-7.
114. Spalletta G. Sertraline treatment of post-stroke major depression: an open study in patients with moderate to severe symptoms. Functional Neurology 2003;18(4):227-32.
115. Stamenkovic M. Fluoxetine in the treatment of poststroke depression: a pilot study. Nervenarzt 1996;67(1):62-7.
116. Wu JP. Clinical observation on acupuncture treatment of 150 cases of post-stroke depression according to syndrome differentiation. Chen Tzu Yen Chiu Acupuncture Research 2010;35(4):303-6.
117. Yuan W. A comparative study of paroxetine in the treatment of post-stroke depression. Henan Journal of Practical Nervous Diseases 2004;7:8-9.
118. Zhang C. The brain-resuscitation acupuncture method for treatment of post wind-stroke mental depression - a report of 45 cases. Journal of Traditional Chinese Medicine 2005;25(4):243-6.
119. Zhao M, Wang ZM, Wang X, Ma JD. The therapeutic observation of fluoxetine single or combined with psychotherapy in the depression succeeding brain stroke. Health Psychology Journal 1999;7(3):241-3.
120. Zhao S, Jia X. Comparative study of the effects of citalopram and amitriptyline on post-stroke depression. Journal of Linyi Medical College 2005;27(5):329-31.
121. Zhao F-T. Citalopiam versus venlafaxine for the improvement of post-stroke depression. Chinese Journal of Clinical Rehabilitation 2005;1(9):12-3.
122. Zheng K. The rehabilitation therapy of cerebral infarction with depressive symptom and its effect on platelet serotonin level. Chinese Journal of Rehabilitation Medicine 2006;21(11):1005-7.
123. Zifko UA. Sertraline in the treatment of post-stroke depression - results of an open multicenter study. Wiener Medizinische Wochenschrift 2002;152(13-14):343-8.
124. Zittel S, Weiller C, Liepert L. Citalopram improves dexterity in chronic stroke patients. Neurorehabilitation and Neural Repair 2008;22(3):311-4.
125. Sitzer M, HuffW, Steckel R. Prevention of poststroke depression after acute ischemic stroke using the selective serotonin reuptake-inhibitor sertraline (PreDis-study). Stroke 2002;33(2):651-2.
126. Whyte E. Sertraline for prevention post-stroke depression and improving rehabilitation outcomes, 2005. www.clinicaltrials.gov (accessed 31 August 2012).
127. Anonymous. Influence of escitalopram on the incidence of depression and dementia following acute middle cerebral artery territory infarction. A randomised placebo-controlled double blind study, 2006. http://www.clinicaltrialsregister.eu.
128. Hankey G. Assessment of fluoxetine in stroke recovery (AFFINITY) trial, 2011. Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au/(accessed 31 August 2012).
129. Carda S, Cisari C. Effects of clinical and functional outcome of escitalopram in adult stroke patients, 2009. www.clinicaltrials.gov (accessed 31 August 2012). [NCT00967408]
130. Kim JS. The preventative effect of escitalopram on depression and related emotional disorders in acute stroke patients, 2011. www.clinicaltrials.gov (accessed 31 August 2012). [NCT01278498]
131. Mead GE, Dennis MS, Innes K, MacLeod M, Sandercock PAG, House A, et al. A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (Fluoxetine Or Control Under Supervision, FOCUS). Proceedings of the 21st European Stroke Conference 2012 (Abst. OAID 26). 2012.
132. Anonymous. Escitalopram improves global cognitive functioning in stroke patients. Australian Journal of Pharmacy 2010;91(1083):86.
133. Anonymous. Fluoxetine enhances motor recovery if given soon after an ischaemic stroke. Australian Journal of Pharmacy 2011;92:91.
134. Berends HI, Nijlant JMM, Movig KLLL, Van Putten MJAM, Jannink MJA, IJzerman MJ. The clinical use of drugs in influencing neurotransmitters in the brain to promote motor recovery after stroke: a Cochrane systematic review. European Journal of Physical and Rehabilitation Medicine 2009;45:621-30.
135. Berends HI, IJzerman MI, Movig KLL, van Putten MJAM. Long term administration of fluoxetine to improve motor recovery after stroke. Future Neurology 2011;6(4):455-7.
136. Bhogal SK, Teasell R, Foley N, Speechley M. Heterocyclics and selective serotonin reuptake inhibitors in the treatment and prevention of post-stroke depression. Journal of the American Geriatrics Society 2005;53:1051-7.
137. Burns MM, Greenberg DA. Antidepressants in the treatment of stroke. Expert Review of Neurotherapeutics 2010;10(8):1237-41.
138. Chen Q. Diagnostic criteria and levels on and evaluation of neurological impairment for stroke patients. Chinese Journal of Neurology 1996;29:376-83.
139. Chen Y, Guo JJ, Zhan S, Patel NC. Treatment effects of antidepressants in patients with post-stroke depression: a meta-analysis. Annals of Pharmacotherapy 2006;40:2115-22.
140. Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for post-stroke depression: a meta-analysis. International Clinical Psychopharmacology 2007;22:159-66.
141. Formulary Staff. SSRI escitalopram improves cognitive function recovery in recent stroke survivors. Formulary 2010;45(4):115.
142. Friedman J. Fluoxetine appears to aid stroke recovery. Neurology Today 2011;11:26.
143. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD003437.pub3]
144. Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD003689.pub3]
145. Hackett ML, Yang M, Anderson CS, Horrocks JA, House A. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD003690.pub3]
146. Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel S. Rate, degree and predictors of recovery from disability following ischemic stroke. Neurology 2007;68:1583-7.
147. Hankey GJ, Spiesser J, Hakimi Z, Carita P, Gabriel S. Time frame and predictors of recovery from disability following recurrent ischemic stroke. Neurology 2007;68:202-5.
148. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bulletin of the World Health Organization 1976;54:541-53.
149. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
150. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
151. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
152. Lang UE, Jockers-Scherubl MC, Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. Journal of Neural Transmission 2004;111:387-411.
153. Lim C-M, Kim W-W, Park J-Y, Kim C, Yoon SH, Lee J-K. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research 2009;87:1037-45.
154. Loubinoux I, Boulanouar K, Ranjeva J-F, Carel C, Berry I, Rascol O, et al. Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. Journal of Cerebral Blood Flow and Metabolism 1999;19:1365-75.
155. Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annual Review of Neuroscience 2005;28:223-50.
156. Palvimaki E-P, Laakso A, Kuoppamaki M, Syvilahti E, Hietala J. Up-regulation of beta l-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology 1994;115:543-6.
157. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
158. Robinson RG, Adams HP. Selective serotonin reuptake inhibitors and recovery after stroke. Lancet Neurology 2011;10(2):110-11. [DOI:10:1016/S1474-4422(10)70326-6]
159. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis antidepressant treatments and animal models of depressive-like behaviour. Behavioural Pharmacology 2003;301:805-9.
160. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behaviour. Behavioural Pharmacology 2007;18:391-418.
161. Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean Journal of Physiology and Pharmacology 2009;13:257-63.
162. Simmonds MC, Higgins JPT, Stewart LA, Tierney JF, Clark MJ, Thompson SG. Meta-analysis of individual patient data from randomised trials: a review of methods used in practice. Clinical Trials 2005;2(3):209-17.
163. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurology 2007;6:182-7.
164. Taupin P. Adult neurogenesis and neuroplasticity. Restorative Neurology and Neuroscience 2006;24:9-15.
165. Van de Meent H, Geurts ACH, Van Limbek. Pharmacological treatment of post-stroke depression: a systematic review of the literature. Topics in Stroke Rehabilitation 2003;10(1):79-92.
166. Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R. Repairing brain after stroke: a review on post-ischaemic neurogenesis. Neurochemistry International 2007;50:1028-41.
167. Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis of post-stroke depression in patients with stroke: a meta-analysis. International Journal of Clinical Practice 2010;64:1310-7.